Eledon Pharmaceuticals, Inc.

ELDNSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1404281

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenues	—	—	—	—	—
Research and Development Expense	$30.3M	$27.1M	$23.7M	$6.1M	$8.1M
Operating Expenses	$43.0M	$88.4M	$36.9M	$18.5M	$16.1M
Operating Income (Loss)	—	-$88.4M	-$36.9M	-$18.5M	-$16.1M
Nonoperating Income (Expense)	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$116.5M	-$88.0M	-$36.9M	-$23.2M	-$16.0M
Income Tax Expense (Benefit)	$0.00	$0.00	-$2.4M	-$404.0K	-$404.0K
Net Income (Loss) Attributable to Parent

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$89.1M	$92.8M	$170.5M	$197.2M	$10.9M
Assets, Current	$56.1M	$59.5M	$88.3M	$115.6M	$10.0M
Cash and Cash Equivalents, at Carrying Value	$4.6M	$56.4M	$84.8M	$114.2M	$8.8M
Liabilities	$81.9M	$8.6M	$6.6M	$6.6M	$1.5M
Liabilities, Current	$3.9M	$6.5M	$4.4M	$2.5M	$1.3M
Accounts Payable, Current	$967.0K	$2.2M	$1.8M	$1.4M	$329.0K
Stockholders' Equity Attributable to Parent	$84.2M	$164.0M	$190.6M	$9.5M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$39.5M	-$28.4M	-$28.9M	-$15.2M	-$13.9M
Net Cash Provided by (Used in) Investing Activities	-$45.3M	-$45.3M	—	$11.0M	$11.0M
Net Cash Provided by (Used in) Financing Activities	$33.0M	$33.0M	-$449.0K	$109.6M	$9.7M
Payments to Acquire Property, Plant, and Equipment	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)